Tepezza™ (teprotumumab-trbw)

Covered: Tepezza (teprotumumab‑trbw) is covered for adults (≥18) with active thyroid eye disease of at least moderate severity for up to a total of 8 infusions (initial 10 mg/kg then seven 20 mg/kg infusions) with a 6‑month authorization; mild/inactive disease or use beyond 8 doses is not covered. Key requirements: prescription/consultation by an ophthalmologist, endocrinologist, or thyroid‑eye‑disease specialist and documentation of diagnosis, clinical activity/severity, prescriber specialty, prior Tepezza dosing history (has not received 8 doses), and a treatment plan consistent with the dosing regimen.

"Documentation that patient is 18 years of age or older."

Sign up to see full coverage criteria, indications, and limitations.